Celeste Bello
Impact in
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
-
- Lymphoma Diagnosis and Treatment
Papers in
-
- Lymphoma Diagnosis and Treatment 51
- Genetics 32
- Chronic Lymphocytic Leukemia Research 28
- Co-authors
- Eduardo M. Sotomayor (17 shared papers)Lubomir Sokol (40 shared papers)Ian W. Flinn (1 shared paper)Sissy Peterman (1 shared paper)Roger G. Ulrich (1 shared paper)Langdon L. Miller (1 shared paper)Heather K. Webb (1 shared paper)Thomas M. Jahn (1 shared paper)
- Journals
- Blood (30 papers)Journal of Clinical Oncology (9 papers)Cancer Control (2 papers)Leukemia Research (2 papers)Blood Advances (2 papers)
- Partner nations
- United StatesBelgiumItaly
In The Last Decade
Celeste Bello
53 papers receiving 1.3k citations
Celeste Bello's Hit Papers
Peers
Comparison fields: 5 of 62
- Genetics 601
- Pathology and Forensic Medicine 719
- Hematology 242
- Oncology 490
- Immunology 218
Countries citing papers authored by Celeste Bello
This map shows the geographic impact of Celeste Bello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Celeste Bello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Celeste Bello more than expected).
Fields of papers citing papers by Celeste Bello
This network shows the impact of papers produced by Celeste Bello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Celeste Bello. The network helps show where Celeste Bello may publish in the future.
Co-authors
The 25 scholars most cited alongside Celeste Bello, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 64 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia Hit paper breakdown → | 2014 | 479 |
| 2 | 2015 | 215 | |
| 3 | 2011 | 86 | |
| 4 | 2007 | 82 | |
| 5 | 2010 | 66 | |
| 6 | 2014 | 58 | |
| 7 | 2011 | 40 | |
| 8 | 2013 | 38 | |
| 9 | 2013 | 33 | |
| 10 | 2019 | 30 | |
| 11 | 2013 | 17 | |
| 12 | 2015 | 14 | |
| 13 | 2016 | 13 | |
| 14 | 2022 | 12 | |
| 15 | 2014 | 12 | |
| 16 | 2012 | 12 | |
| 17 | 2015 | 11 | |
| 18 | 2013 | 11 | |
| 19 | 2008 | 10 | |
| 20 | 2011 | 6 |
About Celeste Bello
Celeste Bello is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Neurology and Pulmonary and Respiratory Medicine, having authored 64 papers that have together received 1.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (51 papers), Chronic Lymphocytic Leukemia Research (28 papers), CNS Lymphoma Diagnosis and Treatment (14 papers), Lung Cancer Treatments and Mutations (9 papers), Viral-associated cancers and disorders (8 papers), Acute Myeloid Leukemia Research (7 papers), Acute Lymphoblastic Leukemia research (7 papers) and CAR-T cell therapy research (5 papers). The work is most often cited by research in Genetics (601 citations), Pathology and Forensic Medicine (719 citations), Hematology (242 citations), Oncology (490 citations) and Immunology (218 citations). Celeste Bello has collaborated with scholars based in United States, Belgium and Italy. Frequent co-authors include Eduardo M. Sotomayor, Lubomir Sokol, Ian W. Flinn, Sissy Peterman, Roger G. Ulrich, Langdon L. Miller, Heather K. Webb, Thomas M. Jahn, Daniel Li and John C. Byrd. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Control, Leukemia Research and Blood Advances.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.